TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
VSTM

Verastem Inc

Healthcare · Biotechnology

7.70$ -0.8% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet VSTM
Line item 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– +1,538.1% +57.4% +34.8% -21.2% +14.6% -26.1% +7.4% +208.8% -47.7% +6.4% -29.6% -12.5% +57.5% -32.2% +142.7%
– – +19.1% +78.6% -6.5% +16.3% -26.7% +8.0% +188.5% -66.5% +70.6% -27.0% -12.2% +54.7% -33.9% +135.3%
– +484.7% -51.8% +87.1% +79.5% -26.6% +30.1% +154.0% +58.0% -66.5% +55.8% -68.6% +252.6% +4.0% +14.0% +130.8%
– – +18.3% +79.1% -8.5% +19.0% -26.6% +7.1% +188.0% -69.8% +87.0% -29.0% -12.3% +56.0% -35.2% +130.8%
– – +203.8% -23.6% +1,808.9% -93.4% +32.5% – – +724.8% -90.5% +115.9% -94.0% +35.5% +376.2% +4,306.5%
– – – – – – – – – +846.8% -100.0% – – – – –
– +8,762.5% +14.4% -22.2% +347.7% -27.5% -30.8% -39.2% +59.0% -30.8% +231.8% -93.3% -56.2% – – –
– – – – – – – – – – – – – – – –
– – – – – – – – – -7.3% – – – – – –
– +19,411.7% -96.6% +218.1% +26.5% +7.5% +6.7% +183.3% +376.3% -9.9% -71.7% -46.0% +125.8% +93.8% +41.2% +45.1%
– +754.9% -23.7% +225.3% +17.9% +9.8% +8.7% +55.8% +116.5% -19.4% -42.8% +8.8% +16.5% +21.8% +17.4% +133.3%
– – – – – – – – -61.5% -92.7% +32.9% +19.5% +60.3% -12.0% +5.7% -46.2%
– +714.7% -18.7% +49.4% +16.5% +22.6% +3.9% +124.3% +11.6% -5.8% -80.6% +22.8% +112.9% +46.6% -44.0% +209.2%
– – – – – – – – +673.8% -9.7% -81.6% -98.7% +9,749.8% +63.4% +1.6% +99.7%
– +1,611.2% +63.4% +29.8% -24.4% +15.4% -29.4% -20.2% +115.5% -94.2% +1,506.8% -24.0% -45.9% +21.1% -150.4% –
– – – – – – – – – – – – – – – –
– +1,758.1% -7.3% +20.9% +13.8% +39.2% +2.9% +3.9% +80.4% +7.6% +105.6% +13.7% +11.0% +36.7% +61.9% +94.1%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?